How Will Real-World Evidence Help Drive Solutions for COVID-19?
(7/19, Managed Healthcare Executive) reports “...COVID-19 adds urgency for the use RWE, said Nancy Dreyer, PhD, MPH, chief scientific officer and senior vice president, Real World Solutions, IQVIA. It's a health crisis on a global scale, and every hour patient records are being collected that could be analyzed to offer a picture of the pandemic. In an interview with Managed Healthcare Executive, Dreyer discussed how RWE might be used, what questions it might answer, and even how it might be collected in the time of COVID.” Full
Aetion, Cegedim Health Data Partner on European RWE Effort
(7/20, Jenni Spinner, Outsourcing Pharma) reports “...Carolyn Magill, CEO of Aetion, said the pharmaceutical development industry must overcome challenges created by the coronavirus pandemic. ‘Over the last few months, COVID-19 has changed the drug development landscape, as leading biopharma companies, regulators, and health technology assessment bodies (HTAs) alike look to real world data to urgently answer questions on treatment utilization, safety, and effectiveness?,’ she said. ‘Through this partnership with Cegedim, our aim is to help global biopharma companies quickly generate decision-grade real-world evidence by expanding our data sources and capabilities in the EU?.’” Full
Indirect Nonhealth Care Costs Drive Total Costs in Psoriatic Arthritis and Psoriasis
(7/18, Laura Joszt, The American Journal of Managed Care) reports “...Patients with both psoriasis and PsA had higher annual total costs than patients who only had 1 disease (75.5% higher than patients with psoriasis and 60.9% higher than patients with PsA). However, the total costs for patients with psoriasis and PsA were similar...‘PsA and [psoriasis] have proved to be diseases with a high economic burden, and the total costs were mainly driven by direct non-healthcare costs,’ the authors concluded.” Full
ICER Posts Draft Scoping Document for the Assessment of Anemia in Chronic Kidney Disease Treatments
(7/20, ICER Press Release) “The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of treatments for anemia in chronic kidney disease. ICER's report will focus on roxadustat (FibroGen, Inc), which is currently undergoing FDA review; a decision is expected at the end of this year.” Full
IQVIA and JDRF Collaborate to Improve Understanding of Type 1 Diabetes Using Real World Data
(7/20, IQVIA Press Release) “...The IQVIA-JDRF collaboration will utilize non-identified real world data to answer important clinical research questions and address areas of unmet need in people with T1D, including how to improve diagnostic accuracy, assess the impact of treatments and monitoring devices on outcomes, and optimize future drug development efforts. In the first project, the team is collaborating to help improve distinctions in diagnosing type 1 vs. type 2 or other diabetes. It is estimated that nearly 40 percent of people with adult-onset T1D may be initially misdiagnosed, so helping differentiate diabetes types will better ensure appropriate treatment and patient outcomes.” Full
Use of Health Savings Accounts Among US Adults Enrolled in High-Deductible Health Plans
Jeffrey T. Kullgren, MD, MS, MPH, et al.
July 17, 2020, JAMA Network Open
JAMA Network Open
Stakeholder-Engaged Derivation of Patient-Informed Value Elements
Susan dosReis, et al.
July 17, 2020, The Patient - Patient-Centered Outcomes Research
Venous Stenting for Patients with Outflow Obstruction and Leg Ulcers: Cost–Effectiveness and Budget Impact Analyses
Carla Rognoni, et al.
July 20, 2020, Journal of Comparative Effectiveness Research
Journal of Comparative Effectiveness Research
Insurance Design and Pharmaceutical Innovation
National Bureau of Economic Research
Anemia in Chronic Kidney Disease: Draft Scoping Document
July 20, 2020
ICER Colloquium Series: Pricing in a Pandemic: Options, Debate, a Path Forward
July 24, 2020
12:00 - 1:30PM ET